FR2489M - Médicament pour le traitement de la dysenterie amibienne. - Google Patents

Médicament pour le traitement de la dysenterie amibienne.

Info

Publication number
FR2489M
FR2489M FR910733A FR910733A FR2489M FR 2489 M FR2489 M FR 2489M FR 910733 A FR910733 A FR 910733A FR 910733 A FR910733 A FR 910733A FR 2489 M FR2489 M FR 2489M
Authority
FR
France
Prior art keywords
drug
treatment
amoebic dysentery
amoebic
dysentery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR910733A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Application granted granted Critical
Publication of FR2489M publication Critical patent/FR2489M/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C07D455/08Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems having an isoquinolyl-1, a substituted isoquinolyl-1 or an alkylenedioxyisoquinolyl-1 radical linked through only one carbon atom, attached in position 2, e.g. emetine
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/26Removing halogen atoms or halogen-containing groups from the molecule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR910733A 1961-09-29 1962-09-28 Médicament pour le traitement de la dysenterie amibienne. Active FR2489M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB35268/61A GB982150A (en) 1961-09-29 1961-09-29 Therapeutic resin complexes

Publications (1)

Publication Number Publication Date
FR2489M true FR2489M (fr) 1964-04-27

Family

ID=10375806

Family Applications (1)

Application Number Title Priority Date Filing Date
FR910733A Active FR2489M (fr) 1961-09-29 1962-09-28 Médicament pour le traitement de la dysenterie amibienne.

Country Status (3)

Country Link
BE (1) BE622943A (fr)
FR (1) FR2489M (fr)
GB (1) GB982150A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076804A (en) * 1975-07-18 1978-02-28 Abbott Laboratories Erythromycin therapy
GB1544761A (en) * 1976-11-26 1979-04-25 Pennwalt Corp Prolonged release pharmaceutical preparations
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
CA2002492A1 (fr) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Compose pharmaceutique contenant une resine echangeuse d'ions
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents

Also Published As

Publication number Publication date
GB982150A (en) 1965-02-03
BE622943A (fr) 1963-01-16

Similar Documents

Publication Publication Date Title
OA03371A (fr) Procédé de préparation de médicaments antériques.
FR2489M (fr) Médicament pour le traitement de la dysenterie amibienne.
FR1316269A (fr) Procédé pour la préparation de poly
BE625529A (fr) Procédé de préparation de 8-hydroxy-quinoléinates métalliques.
NL144279B (nl) Werkwijze voor de bereiding van 3-amino-isoxazolen.
OA00944A (fr) Procédé pour la préparation de sulfapyrimidines.
OA01072A (fr) Procédé pour la préparation de a-pyrrolidino-valérophénones.
FR1961M (fr) Compositions pour le traitement de la toxicomanie.
OA02022A (fr) Procédé de préparation de nouvelles benzène-sulfonylurées.
FR2147M (fr) Médicament pour le traitement des différents syndromes de la sénescence.
FR1338926A (fr) Four pour le traitement de feuillards
BE598665A (fr) Préparations pharmaceutiques pour le traitement de la leucémie.
OA00945A (fr) Procédé pour la préparation de sufapyrimidines.
BE630069A (fr) Composition thérapeutique pour le traitement du parkinsonisme.
FR1596M (fr) Médicament pour le traitement de l'alcoolisme.
FR1476546A (fr) Procédé pour la préparation des 6beta-amino 17beta-carboxy-3alpha, 5alpha-cycloandrostanes et des 3alpha- ou 3beta-amino-17beta-carboxy-5alpha-(ou 5peta)-androstanes
OA00405A (fr) Procédé pour la préparation de nouvelles banzénesulfonyl-semicarbazides.
FR2346M (fr) Médicament pour le traitement des colopathies.
FR1341774A (fr) Procédé pour la préparation de sulfapyrimidines
FR1302193A (fr) Procédé de préparation de 1.3-dialkyl-cyclobuténolones
OA01375A (fr) Préparation de benzène-sulfonyl-semicarbazides.
FR3744M (fr) Médicaments pour le traitement des affections psychiatriques.
FR2817M (fr) Associations de médicaments pour le traitement des désordres mentaux.
FR2148M (fr) Composition topique pour le traitement de verrues.
FR1329M (fr) Compositions pharmaceutiques pour le traitement de la lepre.